- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01536743
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Jonsson Comprehensive Cancer Center at UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Histologically-confirmed ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
- 2. Baseline paraffin embedded tissue from the patient's primary diagnosis is requested before study enrolment and should be forwarded to the designated central laboratory where central assessment of Rb and p16 expression will be performed by using immunohistochemistry. In patients with measurable disease a tissue biopsy may be obtained by core biopsy and submitted to the designated central laboratory.
- GCIG-defined CA125 progression and absence of disease upon imaging or small-volume asymptomatic disease upon imaging and who have progressed following one, two or three lines of chemotherapy for recurrent disease.
- If patients have small-volume disease the current study will be restricted to patients with minimal ascites not causing abdominal distention/mesenteric thickening or not requiring paracentesis, or lesions ≤4 cm by spiral computed tomography [CT] or magnetic resonance imaging [MRI] at baseline.
- Two pretreatment CA125 values (documented on two occasions taken at least one week apart) must be at least twice the upper limit of normal, or twice the nadir value if pretreatment CA125 values never normalized.
- Patients with platinum-sensitive or platinum-resistant disease defined by recurrence or progression of disease > 6 months or ≤ than 6 months after completion of frontline platinum based chemotherapy.
- ECOG performance status ≤ 1 and patients are to be ≥21 years of age.
- Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v.3.0 Grade ≤ 1 and to baseline laboratory values as defined in the inclusion criterion immediately below.
Adequate organ and bone marrow function as evidenced by:
- hemoglobin ≥ 9.0 g/dL
- absolute neutrophil count ≥ 1.5 x 109/L
- platelet count ≥ 100 x 109/L
- Renal function, as follows:
- Serum creatinine ≤ 1.5 x the ULN or calculated creatinine clearance ≥ 40 mL/min
- AST and ALT ≤ 2.5 x ULN
- total bilirubin ≤ 1.5 x ULN unless increase is due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin,
- Adequate coagulation parameters (within 21 days prior to registration), International Normalized Ratio (INR) ≤1.5; Activated ProThrombin Time (APTT) ≤ 1.5 x ULN.
- Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- Informed consent must be obtained in writing for all patients prior to performing study/screening procedures and prior to registration into the study.
Exclusion Criteria
Patients presenting with any of the following will not be included in the study:
- More than 4 prior chemotherapy regimens in the treatment of ovarian cancer.
- Anticipation of immediate need for a major surgical procedure (e.g., impending bowel obstruction, gastrointestinal perforation) or radiation therapy during the trial.
- Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri or breast.
- Treatment with chemotherapy, radiotherapy, surgery, blood products, or an investigational agent within 3 weeks of trial enrolment.
- Any of the following within 6 months prior to trial registration: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event. PD0332991 in Recurrent Ovarian Cancer
- History of brain metastases, spinal cord compression, or carcinomatous meningitis.
- Patient of child-bearing potential is evidently pregnant (eg, positive human chorionic gonadotropin test) or is breast feeding. A woman with child bearing potential is defined as not surgically sterile or being post-menopausal for less than 6 months.
- Patient of child-bearing potential is not willing to use adequate contraceptive precautions. Adequate effective method of contraception are those which result in low failure rates, less than 1% per year, such as non-hormonal IUD, condoms, sexual abstinence or vasectomised partner.
- Known active infection, or on antiretroviral therapy for HIV disease or positive test for chronic hepatitis B or C infection.
- Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the trial.
- Refusal or inability to give informed consent to participate in the trial.
- Corrected QT (QTc) interval >470 msec.
- If radiotherapy is required in a given patient, that patient should be withdrawn from the study.
- Current use or anticipated need for: Food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine.
- Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient's safety, inhibit protocol participation, or interfere with interpretation of trial results, and in the judgment of the investigator would make the patient inappropriate for entry into this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PD0332991
30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach. PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle). |
30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach. PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimate biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian epithelial carcinoma.
Time Frame: 4 weeks
|
CA125 response is defined as ≥ 50% decrease from the baseline CA125 level and confirmed ≥ 21 days after initial evaluation (baseline is defined as the higher value of 2 pre-treatment CA125 assessments).
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity of PD0332991.
Time Frame: 4 weeks
|
Toxicity of PD0332991 will be graded using the NCI Common Toxicity Criteria, version 3.0
|
4 weeks
|
Assess health-related quality of life (HRQL),
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gottfried Konecny, M.D., Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Palbociclib
Other Study ID Numbers
- 11-003234
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Epithelial Carcinoma
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaboratorsRecruitingEpithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IVChina
-
Xian-Janssen Pharmaceutical Ltd.Terminated
-
OHSU Knight Cancer InstituteWithdrawnPrimary Peritoneal Carcinoma | Epithelial Ovarian Carcinoma | Ovarian Carcinoma, Stage 3 or 4United States
-
SOTIO a.s.CompletedOvarian Neoplasms | Ovarian Epithelial CancerCzechia, Poland
-
SOTIO a.s.CompletedOvarian Neoplasms | Ovarian Epithelial Cancer | Ovarian Cancer (OvCa)Czechia, Poland, Germany
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
-
Gynecologic Oncology AssociatesUniversity of North Carolina, Chapel HillUnknownEpithelial Ovarian CarcinomaUnited States
-
SOTIO a.s.TerminatedEpithelial Ovarian CarcinomaGermany, Poland, Czech Republic
-
Johnson & Johnson Pharmaceutical Research & Development...ALZA; Sequus PharmaceuticalsTerminated
Clinical Trials on PD0332991
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedUntreated Operable Early Breast CancerFrance
-
University of FloridaCompletedNon-small Cell Lung CancerUnited States
-
Grupo Español de Investigación en NeurooncologíaPfizerCompleted
-
Grupo Espanol de Tumores NeuroendocrinosCompleted
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
Fondazione Sandro PitiglianiCompleted
-
Washington University School of MedicinePfizerActive, not recruitingBreast NeoplasmsUnited States